Cargando…

Incidental finding of non-alcoholic steatohepatitis-cirrhosis

SUMMARY: A 72-year-old man with type 2 diabetes volunteered to participate in the control group of a clinical study. The study evaluated non-alcoholic fatty liver disease in patients with kidney disease. The patient was followed at a gastroenterology department due to Crohn’s disease and post-operat...

Descripción completa

Detalles Bibliográficos
Autores principales: Adrian, Therese, Hornum, Mads, Knop, Filip Krag, Lotte Gluud, Lise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875068/
https://www.ncbi.nlm.nih.gov/pubmed/36571477
http://dx.doi.org/10.1530/EDM-22-0350
_version_ 1784877880497405952
author Adrian, Therese
Hornum, Mads
Knop, Filip Krag
Lotte Gluud, Lise
author_facet Adrian, Therese
Hornum, Mads
Knop, Filip Krag
Lotte Gluud, Lise
author_sort Adrian, Therese
collection PubMed
description SUMMARY: A 72-year-old man with type 2 diabetes volunteered to participate in the control group of a clinical study. The study evaluated non-alcoholic fatty liver disease in patients with kidney disease. The patient was followed at a gastroenterology department due to Crohn’s disease and post-operative bile acid malabsorption. The patient had no symptoms or biochemical findings suggesting liver disease. Surprisingly, a transient elastography (FibroScan(®)) suggested advanced fibrosis with a median of 16.1 kPa. A liver biopsy showed non-alcoholic steatohepatitis (NASH)-cirrhosis. The diagnosis was only made incidentally and highlights how NASH-cirrhosis may be overlooked due to the lack of symptoms. LEARNING POINTS: Clinicians treating high-risk populations, including patients with type 2 diabetes and/or components of the metabolic syndrome, should be aware of the frequently occurring co-existence with non-alcoholic fatty liver disease (NAFLD) and especially non-alcoholic steatohepatitis (NASH). Liver enzymes may be in the normal range even in people with steatosis, NASH, or even cirrhosis. The diagnosis of NAFLD should include evaluation of hepatic fibrosis as this is the most important prognostic factor for liver-related complications and mortality. Guidelines about systematic screening for NAFLD in patients with type 2 diabetes are incongruent.
format Online
Article
Text
id pubmed-9875068
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-98750682023-02-06 Incidental finding of non-alcoholic steatohepatitis-cirrhosis Adrian, Therese Hornum, Mads Knop, Filip Krag Lotte Gluud, Lise Endocrinol Diabetes Metab Case Rep Unique/Unexpected Symptoms or Presentations of a Disease SUMMARY: A 72-year-old man with type 2 diabetes volunteered to participate in the control group of a clinical study. The study evaluated non-alcoholic fatty liver disease in patients with kidney disease. The patient was followed at a gastroenterology department due to Crohn’s disease and post-operative bile acid malabsorption. The patient had no symptoms or biochemical findings suggesting liver disease. Surprisingly, a transient elastography (FibroScan(®)) suggested advanced fibrosis with a median of 16.1 kPa. A liver biopsy showed non-alcoholic steatohepatitis (NASH)-cirrhosis. The diagnosis was only made incidentally and highlights how NASH-cirrhosis may be overlooked due to the lack of symptoms. LEARNING POINTS: Clinicians treating high-risk populations, including patients with type 2 diabetes and/or components of the metabolic syndrome, should be aware of the frequently occurring co-existence with non-alcoholic fatty liver disease (NAFLD) and especially non-alcoholic steatohepatitis (NASH). Liver enzymes may be in the normal range even in people with steatosis, NASH, or even cirrhosis. The diagnosis of NAFLD should include evaluation of hepatic fibrosis as this is the most important prognostic factor for liver-related complications and mortality. Guidelines about systematic screening for NAFLD in patients with type 2 diabetes are incongruent. Bioscientifica Ltd 2022-12-06 /pmc/articles/PMC9875068/ /pubmed/36571477 http://dx.doi.org/10.1530/EDM-22-0350 Text en © The authors https://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Unique/Unexpected Symptoms or Presentations of a Disease
Adrian, Therese
Hornum, Mads
Knop, Filip Krag
Lotte Gluud, Lise
Incidental finding of non-alcoholic steatohepatitis-cirrhosis
title Incidental finding of non-alcoholic steatohepatitis-cirrhosis
title_full Incidental finding of non-alcoholic steatohepatitis-cirrhosis
title_fullStr Incidental finding of non-alcoholic steatohepatitis-cirrhosis
title_full_unstemmed Incidental finding of non-alcoholic steatohepatitis-cirrhosis
title_short Incidental finding of non-alcoholic steatohepatitis-cirrhosis
title_sort incidental finding of non-alcoholic steatohepatitis-cirrhosis
topic Unique/Unexpected Symptoms or Presentations of a Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875068/
https://www.ncbi.nlm.nih.gov/pubmed/36571477
http://dx.doi.org/10.1530/EDM-22-0350
work_keys_str_mv AT adriantherese incidentalfindingofnonalcoholicsteatohepatitiscirrhosis
AT hornummads incidentalfindingofnonalcoholicsteatohepatitiscirrhosis
AT knopfilipkrag incidentalfindingofnonalcoholicsteatohepatitiscirrhosis
AT lottegluudlise incidentalfindingofnonalcoholicsteatohepatitiscirrhosis